BaseSpace
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Diabetes mellitus, Endothelial cell, Human chorionic gonadotropin, Rosiglitazone)
Bookmark Forward

QuickView for PVRIG (gene)


Body Atlas

Most Correlated Tissues

  1. Thymus gland
  2. B lymphocyte (IgM memory) of spleen
  3. B lymphocyte (naive) of spleen
  4. T Lymphocyte (CD8+) of peripheral blood
  5. Natural killer cell of peripheral blood
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Sepsis due to Escherichia coli
  2. Ataxia-telangiectasia syndrome
  3. Septicemia due to Klebsiella
  4. Protozoan infection
  5. Placental insufficiency
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Histone Deacetylase Inhibitors
  2. trabectedin
  3. Mephenesin
  4. 4-1BB Ligand
  5. Fluspirilene
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. MIR508
  2. RNPC3
  3. SLC7A5
  4. NPAT
  5. ILF3
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand …
  2. PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.
  3. PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia
  4. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human …
  5. Nonredundant Upregulation of CD112R (PVRIG) and PD-1 on Cytotoxic T Lymphocytes Located in T Cell Ne…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
  2. COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
  3. A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanc…
  4. COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
  5. COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.